After being fired, I became the light of medicine

Chapter 170 New drug-nano-nodule contrast agent!

"I'm sorry, Evans, I hurt you just now."

"Fcuk, Zhang! When you grabbed my collar just now, I really thought you were crazy! Don't play such a joke on me next time, or I will turn against you!"

"Okay, Evans."

Zhang Yang returned to normal and said apologetically, then sat down in front of a computer next to Evans.

After a while, as he communicated more deeply with Evans, he obtained more detailed and effective information.

This is indeed the same as Evans said, an "Adrev" biological laboratory located in Norway, Europe.

Dr. Eric, the head of the laboratory, is one of the top molecular biology experts in Europe. His main research direction is to evaluate the activation effect of respiratory microbiota on lung cancer carcinogens and identify risk factors for lung cancer susceptibility.

And the identity of his host and Evans in front of him are also experts in the field of lung cancer!

It can be said that this is a top-notch biological laboratory with extensive experience in lung cancer research.

After understanding the information about the scenes, Zhang Yang immediately focused on how to complete the simulation plot.

Based on past experience, if we want to complete the simulation plot next, we will most likely have to start with Evans in front of us and promote the development of the plot from him.

But when Zhang Yang tried various methods to find clues from Evans, Evans always looked surprised and confused, and finally reminded Zhang Yang to quickly complete the statistical task assigned by "Dr. Eric".

What surprised Zhang Yang even more was that in the past simulations, if no clues were found after a certain period of time, the simulator would automatically end and return to the void.

But this time, a full fifteen minutes were wasted, and the simulation plot showed no sign of ending.

"Could it be that the plot this time is not an 'exploration mission', but just requires completing some statistical task that Evans mentioned?"

"It can't be that simple, can it?"

Zhang Yang was a little bit unbelievable, but the next second he still focused on the statistical task.

As a top drug developer, Zhang Yang has some understanding of biological laboratories.

The first thing to make clear is that biological laboratories and drug research and development centers are two different things.

In terms of nature, biological laboratories are more inclined towards scientific research, while pharmaceutical companies' drug research and development centers are more commercial operations.

For example, the main work of the Adleev Biological Laboratory is not to develop drugs to treat lung cancer; they focus on the research of lung cancer, so the focus of their work is at the microscopic level and on the pathological mechanism.

To be more specific, their daily work involves culturing various lung cancer cells, and then using cell models to study the physiological functions and pathological changes of these cancer cells.

For example, a virus suspected of causing lung cancer can be used to infect normal lung epithelial cells and observe changes in cell metabolism, gene expression, and cell apoptosis or proliferation.

For example, we will study how lung cancer cells transmit signals with surrounding immune cells and fibroblasts, and other very microscopic research.

The purpose, of course, is to fully understand the operating mechanism of a lung cancer cell.

Once these research results have made progress, they will be published in the world's top medical journals, which will not only bring them a lot of industry fame, but also attract some pharmaceutical companies to seek business cooperation and technical support.

It can be said,
From a certain perspective, the top biological laboratories around the world are the "upstream" of pharmaceutical companies.

They have provided a lot of basic research on various diseases, viruses, and bacteria, and provided a theoretical foundation for pharmaceutical companies' drug development.

The statistical data that Evans mentioned is also an important part of biological laboratory research on a disease and is important basic data.

"Evans, what did you just say I wanted to count?!"

"My god! Zhang, what's wrong with you today?"

"You are responsible for collecting statistics on the incidence and various characteristics of 'lung adenocarcinoma' in the Nordic population over the past ten years and the past five years; and I am responsible for the Asian population!"

"Okay, thank you Evans, I got it."

For the first time, Zhang Yang began to take Evans' statistics seriously.

To be honest, this job is not difficult. It is nothing more than screening out the large amount of patient data collected and incorporating it into the patient database.

The only difficulty is that there are too many data items involved.

In addition to basic information such as name, age, family history, etc., it even includes the patient's DNA, gene analysis and protein expression.

Zhang Yang was a little surprised how such detailed patient data were obtained!
You know, these are the patients' most sensitive personal and genetic information. If they are accidentally exposed, it is very likely to bring serious consequences to the patients.

and!

The most terrifying thing is,
These detailed data are not just one or two. At a glance, the data that needs to be counted on his computer is as high as tens of thousands!

"Huh...are the data collected by these top biological laboratories abroad so complete? DNA, gene sequencing, and protein expression...too detailed!"

"But how long will it take to enter these tens of thousands of pieces of data?!"

Zhang Yang sighed, but had no choice but to start entering the patient data into the computer.

One hour, two hours, three hours.

Zhang Yang's eyes were dazzled, but he finally confirmed that this simulation plot was not an "exploration mission" like the previous ones, but a continuous mission.

Two hours later, Evans and several other staff members went off work one after another. Zhang Yang felt his scalp tingling when he saw that there were still 1.4 pieces of patient data that had not been counted.

"There is still so much data left. It is definitely unrealistic to finish it all at once!"

"Will this simulation be 'saved' and continued tomorrow?!"

Thinking of this, Zhang Yang decided to try to leave the biological laboratory like Evans.

Walking out of the laboratory door, it was true!

The screen suddenly went black, and Zhang Yang directly exited the simulation and returned to the void.

"Good guy, it's true!"

张扬的猜测没错，等第二天再次进入模拟时，他发现模拟剧情的时间从昨天的2018年8月9日变成8月10日。

And the last piece of patient data entered yesterday also remained at the moment I left the laboratory.

"Well, it seems that the task of this scenario simulation is to enter all these more than 10,000 pieces of data into the database!"

Zhang Yang determined the direction for completing the simulation plot mission. In the next few days, he devoted almost all his energy to data entry.

Three days later, a total of 1.8 data on Nordic people suffering from "lung adenocarcinoma" were entered into the laboratory database!
Zhang Yang breathed a sigh of relief. Now he could finally complete the task, right?
But no matter how long he waited, the simulation plot showed no sign of ending. When his eyes fell on Evans standing beside him, a sudden idea flashed in his mind.

"Does it mean that Evans needs to be included in the statistics?" "It's possible!"

Thinking of this, Zhang Yang immediately turned to Evans beside him.

"Evans, I have completed the statistics of all patients, what about you?"

Evans smiled bitterly and shook his head:
"Zhang, you have to wait for me for a moment. Your data on the Nordic race is only 1.8, but the data on the Asian race I have here is much more than yours!"

"You have to know that China has the highest incidence of lung cancer, at 37.5%... So you have too much data. Fortunately, I have been entering it a few days in advance..."

Zhang Yang had been immersed in the thought of completing the task in the past few days, and only then did he pay special attention to the Asian race that Evans mentioned.

However, he couldn't help at this time and could only wait patiently for Evans to enter the final data into the database.

"Okay, hurry up!"

After waiting for nearly four hours, Evans finally completed his work.

"Finally, Zhang! How's it going? What's the result of your Nordic race statistics?"

Zhang Yang had already become impatient, so he handed the statistical data he had compiled to Evans and said:
“This time, a total of 1.8 patients with ‘lung adenocarcinoma’ of Northern European descent were counted;
Compared with the data from ten years ago, the proportion of lung adenocarcinoma has slightly increased from 39% to 40%. This data shows that the incidence of lung adenocarcinoma has not increased in the past decade. "

"At least in northern European populations, the incidence of lung adenocarcinoma is not elevated."

"In terms of gender distribution, the data is almost the same as ten years ago, with males accounting for 64% and females accounting for 36%... It can be said that lung adenocarcinoma is still mainly male-dominated."

“除此以外，发病年龄也依然是50岁以后占比70%，35-50岁占比20%，35岁以下占比10%。”

"It can be said that judging from the basic perspectives of age, gender, and incidence, the prevalence of lung adenocarcinoma has not changed much in the Nordic population in the past decade."

"How about you, Evans? How about Asian race?"

Evans also handed the sorted data to Zhang Yang for review.

"In the past decade, from 2008 to 2018, the incidence rates of Asians and Northern Europeans were almost the same in terms of gender and age."

"Lung adenocarcinoma accounts for 41% of lung cancer in Asians, 65% in men, and 50% in patients over 72 years old!"

"Based on the above basic data, we can draw a basic conclusion that in the past decade, there is no significant difference in the incidence characteristics of 'lung adenocarcinoma' between Asians and Europeans."

"It can be said that the cause of 'lung adenocarcinoma' has almost no obvious relationship with race!"

Zhang Yang nodded:
"That's understandable."

After he finished speaking, Evans smiled and handed the two sets of organized data results back to Zhang Yang.

"Zhang, thank you for your hard work. I finally completed the task assigned by Dr. Eric on time. Let's have dinner together after get off work!"

“I know a good Italian restaurant…”

As Evans was speaking, Zhang Yang was thinking about why he hadn't completed the simulation task yet.

Just when Zhang Yang was feeling a little flustered, Evans in front of him finally became blurry, and then a long list of rewards suddenly appeared before his eyes.

[“Biological Laboratory”——The first phase of the plot simulation is over! ]

[Completion: 100%]

[This simulation score: B]

【Achievement Ending: Complete Statistics】

【Evaluation: To understand a disease, we need not only to understand its internal pathogenesis and viral pathology, but also to conduct a more in-depth study of the differences between different races through the statistics of patient data of different races, and to find effective targets for the disease. 】

Although statistics is very basic, it plays a key role in the analysis and research of various diseases.

[The host has successfully completed a large amount of data statistics, well done! ]

[This simulation has been completed effectively, you can check the ending. ]

[Reward: 300 energy points]

【Award: "Nano-nodule developer" crystal form patent, synthesis route, and synthesis process. 】

【Reward: Data analysis of pharmacokinetics, toxicokinetics, ethics, acute toxicity, and chronic toxicity of "nano-nodule contrast agent". 】

【Reward: Complete data of Phase I and Phase II clinical trials of “Nano-nodule imaging agent”. 】

[Reward: 'CT machine' special radiation spectrum imaging technology. ]

Energy value 300 points!
Zhang Yang was delighted, the simulated plot was still the best!

In just a few days...

wrong!

His eyes quickly fell on the most crucial drug reward, and his heart suddenly trembled violently.

Nano nodule developer?
Judging from the name... this wouldn't be a drug for lung nodules, right?

Restraining his excitement, Zhang Yang quickly clicked on the instruction sheet on the light blue screen. After just a few seconds, his eyes widened with disbelief!

What the hell!

It really is a medicine for lung nodules!
and,

It’s not a therapeutic drug, but the lung nodule identification drug that I have been thinking about recently!
Identify whether it is a benign or malignant nodule!
Nano-nodule developer:
After the contrast agent is injected into the human body through the veins, its active ingredients will quickly reach the lung tissue and quickly combine with the specific molecular markers of "solid nodules" and "ground glass nodules" on the lung tissue.

If it is a benign nodule, there will be no changes after the markers on its cell surface and the drug components combine!
Once the drug components bind to the specific molecular markers of malignant nodules, the bound nodules will emit specific fluorescent signals.

This fluorescent signal can be displayed as red in the CT image through the improved "special radiation spectrum CT machine", thereby alerting medical staff that the nodule is a malignant nodule!
After seeing the end, Zhang Yang was completely shocked!
Recently he has been thinking about how to use drugs to distinguish benign and malignant nodules, but he did not expect that the contrast agent provided by the system would be such a solution!
First, use the drug and the markers of malignant nodules to combine to form a fluorescent reaction!

Then by changing the spectrum of the CT machine, the imaging results can be fed back!
I have to say, this idea is really awesome!

Zhang Yang sighed, but soon he became excited.

With the emergence of this lung nodule contrast agent, how many patients suffering from lung nodules will be given hope? !

All patients with lung nodules no longer need to worry about gains and losses or being misdiagnosed!

The tragedy of Director Feng Gang will never happen again!
(End of this chapter)